ClinicalTrials.gg
RecruitingNCT05534971Updated Jan 6, 2026

Central Line Study

A Phase 4 interventional study of Central venous catheter insertion in Shock, sponsored by Montefiore Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Montefiore Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Shock with a site in United States — 12 open to participants now, 18 under way, 1 of them phase 3. Shock · United States.

Planned enrollment
20th of 49
160 · median 100
Started
2022
with 4 others
Phase 4
9 of 83
6 open now
Primary completion
2027-12
later than 12 of 17 live
Registered
70th of 83
by date
Lead sponsor
2 of 83
Montefiore Medical Center

Among the 83 studies in Shock with a site in United States, this one is the 20th largest by planned enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2022, is one of 9 in phase 4, reaches primary completion later than 12 of the 17 other live ones, and was the 70th registered.

Shock

487 studies on the registry are indexed under Shock; 107 are open to participants now.

Browse Shock studies →

Open to participants now

12 of the 83 studies in Shock with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Shock with a site in United States, or all of them as a file.
02

Study summary

Two different techniques for placing a central venous catheter will be compared. The studyu team hypothesizes that clinicians randomized to the peripheral catheter technique will have higher first attempt success rates, fewer procedural complications, and a shorter mean time to procedure completion than physicians assigned to wire through hollow bore needle.

Read the detailed description

Central venous catheterization (CVC) is a lifesaving procedure carried out by emergency and acute care physicians to access proximal blood vessels in order to deliver medications, blood products and other resuscitative agents. Typically, this access is achieved by threading a wire through a hollow bore needle and then placing the central venous catheter over the wire. This procedure, called the Seldinger technique, results in the cannulation of the femoral or internal jugular veins. Nowadays, physicians use concurrent ultrasound guidance rather than an anatomic landmark-based approach to increase the success rate of central venous catheterization. The wire through hollow bore needle approach requires the use of two hands to hold the needle in the vessel in order to pass a guidewire. When done under ultrasound guidance, this requires dropping the ultrasound probe in order to have both hands available to achieve vessel cannulation.

Recent research has demonstrated that cannulation of central veins can be obtained by first using a peripheral intravenous catheter rather than a hollow bore needle. This technique requires just one hand, thereby allowing the physician to continue use of the ultrasound. Furthermore, the peripheral intravenous catheter is more stable within the vein than the hollow bore needle and less likely than the needle to damage the vessel wall when the catheter is jiggled. This is the same technique used to place mid-lines, a hybrid technique that incorporates the Seldinger technique and a peripheral intravenous catheter.

03

Conditions studied

  • Shock

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients in the emergency department who require ultrasound guided central line placement are eligible for participation and will be referred for participation in the study by the clinical team.

Exclusion criteria

Exclusion Criteria:

  • Inherited, acquired, or medication related coagulopathy or thrombocytopenia ( \< 100,000). Patients will not be excluded for use of aspirin or other anti-platelet medication.
  • Previous central venous access at the same anatomical site.
  • Any indwelling catheter or wire that could potentially interfere with central line placement
  • Anterior border of the target vein deeper than 3.5cm

Or for any clinical feature that would interfere with obtaining including dementia, delirium, or encephalopathy, as determined by the clinical attending physician.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Standard technique

    The conventional hollow bore needle on a syringe will be used

    Procedure: Central venous catheter insertion

  • Experimental
    Peripheral IV

    A peripheral intravenous catheter will be used to obtain initial central venous access

    Procedure: Central venous catheter insertion

Interventions

  • ProcedureCentral venous catheter insertion

    The clinical team will use the technique to establish central venous access

06

What researchers measure

Primary outcomes

  1. Only 1 attempt

    The frequency with which the central line can be placed with only one attempt will be summarized. Each attempt is defined by skin penetration

    Time frame: 20 minutes

Secondary outcomes

  1. Unable to place central line

    The frequency with which the clinical team is unable to place the central line at that clinical site using the assigned technique will be summarized by study arm.

    Time frame: 20 minutes

  2. Number of attempts

    Total number of required attempts (skin penetration) will be summarized by study arm.

    Time frame: 20 minutes

  3. Number of attempted guidewire passages

    Total number of attempted guidewire passages, defined as the number of times a guidewire must be attempted to be passed, will be determined. Results will be summarized by study arm.

    Time frame: 20 minutes

  4. Time taken for completion of the procedure

    The duration of time from skin penetration to wire out will be summarized by study arm using basic descriptive statistics.

    Time frame: 20 minutes

  5. Procedure-related adverse events

    Procedure related adverse events including pneumothorax, incorrect vessel cannulation, and bleeding requiring application of pressure will be summarized by study arm.

    Time frame: 20 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 10, 2022
StartActual
Nov 16, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05534971
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
Nov 16, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 6, 2026

Study contacts

Joe Offenbacher, MD
Contact
joseph.offenbacher@nyulangone.org
646-929-7815
Benjamin Friedman, MD
Contact
bfriedm@montefiore.org
718-920-6626
Benjamin J Friedman, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion